Abuse potential and pharmacological comparison of tramadol and morphine

doi:10.1016/0376-8716(91)90081-9

Drug and Alcohol Dependence

Volume 27, Issue 1, January 1991, Pages 7-17

https://doi.org/10.1016/0376-8716(91)90081-9 Get rights and content

Abstract

The purpose of the study was to assess the abuse potential of the opioid analgesic tramadol. Tramadol (75, 150 and 300 mg), morphine (15 and 30 mg) and placebo were tested intramuscularly in volunteer non-dependent opiate abusers. Subjective, behavioral and miotic changes were assessed prior to dosing and intermittently for 12 h after drug administration. Morphine produced typical subjective effects, opiate identifications and miosis. Tramadol 75 and 150 mg were not different from placebo. Although tramadol 300 mg was identified as an opiate, it produced no other morphine-like effects. These findings suggest that tramadol has a low abuse potential by the parenteral route.

References (20)

D.R. Jasinski et al.
Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects
Drug Alcohol Depend.
(1986)
H.P. Andrews et al.
Graphical display of means
Am. Statistician
(1980)
I. Arend et al.
Tramadol and pentazocine-a clinical double- blind cross-over comparison
Arzneim.-Forsch./Drug Res.
(1978)
W.G. Cochran et al.
Experimental Designs
(1957)
B. Driessen et al.
Effects of tramadol on noradrenaline release from rat brain cortex slices
Naunyn-Schmiedeberg's Arch. Pharmacol.
(1989)
D.J. Finney
Statistical Method in Biological Assay
(1964)
L. Flohe et al.
Clinical study on the dependence development in long-term administration of tramadol
Arzneim.-Forsch./ Drug Res.
(1978)
E. Friderichs et al.
Pharmacological investigations on analgesia and the development of dependence and tolerance with tramadol, a strongly acting analgesic
Arzneim.- Forsch./Drug Res.
(1978)
H.-H. Hennies et al.
Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids
Arzneim.-Forsch./Drug Res.
(1988)
H.P. Huber
Study of the psychological effects of a new analgesic of the cyclohexanol series. A contribution to the clarification of the psychological dependence potential of tramadol
Arzneim.-Forsch./Drug Res.
(1978)

There are more references available in the full text version of this article.

Cited by (234)

The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review
2024, American Journal of Medicine
Pain is prevalent in patients with cirrhosis. Due to potential alterations in drug metabolism, risk for adverse effects, and complications from cirrhosis, physicians are often faced with difficult choices when choosing appropriate analgesics in these patients. Overall, acetaminophen remains the preferred analgesic. Despite its potential for intrinsic liver toxicity, acetaminophen is safe when used at 2 g/d. In contrast, non-selective nonsteroidals should be avoided due to their multiple side effects, including worsening renal function, blunting diuretic response, and increasing risk of portal hypertensive and peptic ulcer bleeding. Celecoxib can be administered for short term (≤5 days) in patients with Child's A and Child's B cirrhosis (50% dose reduction). Opioids carry the risk of precipitating hepatic encephalopathy and should generally be avoided, when possible. If clinical situation demands their use, opioid use should be limited to short-acting agents for short duration. Gabapentin and pregabalin are generally safe. Duloxetine should be avoided in hepatic impairment. Topical diclofenac and lidocaine seem to be safe in patients with cirrhosis.
Application of oxidized multi-walled carbon nanotubes and zeolite nanoparticles for simultaneous preconcentration of codeine and tramadol in saliva prior to HPLC determination
2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
In this work, a dispersive micro-solid phase extraction technique along with high-performance liquid chromatography-UV detection was developed for simultaneous preconcentraion and determination of trace levels of codeine and tramadol in human saliva. This method is based on the adsorption of codeine and tramadol on a mixture of oxidized multi-walled carbon nanotubes and zeolite Y nanoparticles with 1:1 ratio as an efficient nanosorbent. Various analytical parameters influencing the adsorption step including the amount of adsorbent, the pH of the sample solution, the temperature, the stirring rate, the contact time of the sample solution, and the adsorption capacity were investigated. Based on the results, 10 mg adsorbent, sample solutions with pH = 7.6, temperature of 25 °C, stirring rate 750 rpm and contact time 15 min, in the adsorption step shows the best results for both drugs. Then the effective parameters on the analyte desorption stage such as the type of desorption solution, pH of the desorption solution, desorption time and desorption volume were investigated. Studies have shown that water/methanol (50:50 v/v) as desorption solution, pH = 2.0, desorption time of 5 min and desorption volume of 2 ml gives the best results.Chromatographic separation was performed on a RP-Shim-pack CLC-ODS-C18 column (250 mm × 4.6 mm, 5 µm) with isocratic mode. The mobile phase contained of acetonitrile:phosphate buffer (18:82, v/v) at pH = 4.5 and the flow rate was 1 ml.min⁻¹. The wavelength of UV detector was adjusted at 210 nm and 198 nm for codeine and tramadol, respectively.Under optimum conditions, the extraction efficiencies of 98.5% and 99.2% were achieved for codeine and tramadol respectively. Enrichment factor of 13, detection limit of 0.3 μg L⁻¹, relative standard deviation of 4.07 for codeine; and an enrichment factor of 15, a detection limit of 0.15 μg L⁻¹, and standard deviation of 2.06 for tramadol were calculated. The linear range of the procedure for each drug was 1.0 to 1000 μg L⁻¹. This method was successfully applied for the analysis of codeine and tramadol in saliva samples.
Reinforcing effect of tramadol in the rat
2023, Neuroscience Letters
Tramadol is one of the most commonly prescribed analgesic opioids in various pharmacopeias. Tramadol has been linked to abuse in recent clinical investigations. However, the behavioral effects and neural substrates of the drug have not been well characterized in preclinical studies. As a result, the present study investigated the effects of tramadol on behavioral sensitizations in rats. Its impacts on cellular and molecular alterations in the brain were also investigated. In conditioned place preference (CPP) paradigm, tramadol induced behavioral as well as motor sensitizations. These effects were dramatically reduced by intraperitoneal administration of naltrexone, an opioid receptor antagonist. Tramadol caused changes in several molecular markers (pERK1/2, Δ-FosB, PKCγ, PKMζ GAD67) in the anterior cingulate cortex, which could indicate an increase in excitation within this structure. Tramadol is demonstrated in the present study to be a reinforcing drug in rats, as it increased both behavioral and motor sensitizations. Tramadol’s effects are most likely due to the high levels of excitation it causes in the brain, which is mostly caused by the activation of opioid receptors.
A comparison of perioperative pain control in total shoulder arthroplasty: preoperative tramadol is associated with decreased long-term opiate use when compared with traditional opioids
2021, Seminars in Arthroplasty JSES
Prolonged opiate use has been associated with adverse patient outcomes and high societal costs. While tramadol, an alternative to traditional opiate pain medications, has evidence-based support for the treatment of knee osteoarthritis, no clear guidance exists in the shoulder arthroplasty literature to guide perioperative prescribing practices.
All patients from a private insurance database who underwent total or reverse shoulder arthroplasty between 2008 and 2015 were identified. These patients were grouped into 3 mutually exclusive cohorts based on perioperative pain management regimes: those who received (1) traditional opiates only, (2) tramadol only, (3) nonopioids only. These groups were compared for length of stay, prolonged opioid use (defined as opioid use >3 months after surgery), emergency department (ED) visits, 90-day readmissions, and medical complication
From 2008 to 2015, 5,797 shoulder arthroplasty patients met inclusion criteria for the study. Of those, 498 (8.6%) received pre- and postoperative tramadol, 2001 (34.5%) traditional opioids, and 3289 (56.7%) nonopioids only. Traditional opioid use was weakly associated with a higher risk of minor medical complications (odds ratio [OR] 1.20, confidence interval [CI] 1.00-1.97, P = .048), ED visits (OR 1.22, CI 19 1.03-1.43, P = .017), and 90-day readmission (OR 1.29, 1.03-1.62, P = .025) compared to nonopioid only users. Additionally, these patients had a markedly higher risk of prolonged narcotic use (OR 6.72, CI 5.89-7.68, P < .001).
Shoulder arthroplasty who received perioperative tramadol were less likely than those who received traditional opioids to require prolonged opiate pain medication. Given the well-established negative consequences of prolonged opiate use and lack of association between tramadol use and medical complications found in the current study, tramadol should be considered in shoulder arthroplasty candidates. However, tramadol is not without its own risks, and the risk of prolonged postoperative narcotic use is still higher within this population compared to those patients who take no opioids. These results should help inform preoperative pain management plans in patients who are likely to undergo eventual TSA.
Level III; Retrospective Cohort Study
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management
2021, Genetics in Medicine
Cytochrome P450 2D6 (CYP2D6) genotype–guided opioid prescribing is limited. The purpose of this type 2 hybrid implementation-effectiveness trial was to evaluate the feasibility of clinically implementing CYP2D6-guided postsurgical pain management and determine that such an approach did not worsen pain control.
Adults undergoing total joint arthroplasty were randomized 2:1 to genotype-guided or usual pain management. For participants in the genotype-guided arm with a CYP2D6 poor (PM), intermediate (IM), or ultrarapid (UM) metabolizer phenotype, recommendations were to avoid hydrocodone, tramadol, codeine, and oxycodone. The primary endpoints were feasibility metrics and opioid use; pain intensity was a secondary endpoint. Effectiveness outcomes were collected 2 weeks postsurgery.
Of 282 patients approached, 260 (92%) agreed to participate. In the genotype-guided arm, 20% had a high-risk (IM/PM/UM) phenotype, of whom 72% received an alternative opioid versus 0% of usual care participants (p < 0.001). In an exploratory analysis, there was less opioid consumption (200 [104–280] vs. 230 [133–350] morphine milligram equivalents; p = 0.047) and similar pain intensity (2.6 ± 0.8 vs. 2.5 ± 0.7; p = 0.638) in the genotype-guided vs. usual care arm, respectively.
Implementing CYP2D6 to guide postoperative pain management is feasible and may lead to lower opioid use without compromising pain control.
Tramadol as an analgesic
2021, Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics
Moderate to severe pain represents a major health problem and has a significant impact on the quality of life. Tramadol is an atypical opioid and one of the most common effective analgesics that is prescribed to relieve different forms of acute and chronic pain, and pain of moderate to severe intensity. Tramadol binds weakly to the μ-opioid receptor (MOR) and differs from typical opioid drugs such as morphine as it affects and modulates the reuptake of the monoamines noradrenaline and serotonin (5HT). Since tramadol has a lower affinity to the MOR, more satisfactory and less adverse effects in comparison with these of the classical opioids were obtained. Therefore, several literatures investigated the opioids-associated adverse events and risks excluded tramadol. Tramadol is highly effective in neuropathic pain, osteoarthritis pain, cancer pain, pain in the emergency department, acute myocardial infarction pain, postoperative pain, postoperative shivering, acute renal pain and as a local anesthetic. In this chapter, we focused on the analgesic effect of tramadol along with its chemistry, pharmacokinetics, mechanism(s) of action, drug interactions and contraindications and adverse effects.

View all citing articles on Scopus

View full text

Abuse potential and pharmacological comparison of tramadol and morphine

Abstract

Drug Alcohol Depend.

Graphical display of means

Am. Statistician

Tramadol and pentazocine-a clinical double- blind cross-over comparison

Arzneim.-Forsch./Drug Res.

Experimental Designs

Effects of tramadol on noradrenaline release from rat brain cortex slices

Naunyn-Schmiedeberg's Arch. Pharmacol.

Statistical Method in Biological Assay

Clinical study on the dependence development in long-term administration of tramadol

Arzneim.-Forsch./ Drug Res.

Pharmacological investigations on analgesia and the development of dependence and tolerance with tramadol, a strongly acting analgesic

Arzneim.- Forsch./Drug Res.

Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids

Arzneim.-Forsch./Drug Res.

Study of the psychological effects of a new analgesic of the cyclohexanol series. A contribution to the clarification of the psychological dependence potential of tramadol

Arzneim.-Forsch./Drug Res.